Fan Qing Meng
Chief Executive Officer at Shandong Bestcomm Pharmaceutical Co., Ltd.
Network origin in Fan Qing Meng first degree
Entity | Entity type | Industry | |
---|---|---|---|
Shandong Bestcomm Pharmaceutical Co., Ltd.
Shandong Bestcomm Pharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Shandong Bestcomm Pharmaceutical Co., Ltd. is engaged in the research, development and production of domestic pharmaceutical technology. It also offers the development of various new drugs. The company was founded on August 2, 2000 and is headquartered in Jinan, China.
1
| Private Company | Miscellaneous Commercial Services | 1 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Fan Qing Meng via their personal network
Company | Sector | Related people | Main position |
---|---|---|---|
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. | Pharmaceuticals: Major | Director/Board Member | |
CASI PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Qinghai Nationalities University | College/University | Undergraduate Degree | |
IDG Capital | Director/Board Member | ||
Shenzhen Investment Holdings Co., Ltd.
Shenzhen Investment Holdings Co., Ltd. Financial ConglomeratesFinance Shenzhen Investment Holdings Co., Ltd. operates as a state-owned asset management company. Its business activities include management of properties, capital operation, investment and financing, transportation logistics, manufacturing and trading, and modern service industries. The company was founded on October 13, 2004 and is headquartered in Shenzhen, China. | Financial Conglomerates | Corporate Officer/Principal | |
Hexie Zhuorui Zhuhai Investment Management Co. Ltd. | Corporate Officer/Principal | ||
Hangzhou Sciwind Biosciences Co., Ltd.
Hangzhou Sciwind Biosciences Co., Ltd. BiotechnologyHealth Technology Hangzhou Sciwind Biosciences Co., Ltd. is a biopharmaceutical company based in Hangzhou, China. The Chinese company's product pipeline includes potentially first-in-class and drug candidates, such as the long-acting glp-1 peptide analog ecnoglutide (phase 3), oral glp-1 peptide analog xw004 (phase 1), and oral small molecule glp-1 receptor agonist xw014 (phase 1). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms, and identified a series of drug candidates based on these core platform technologies. The company was founded in 2017 by Hai Pan, who has been the CEO since 2017. | Biotechnology | Director/Board Member | |
SHANGHAI MODEL ORGANISMS CENTER, INC. | Miscellaneous Commercial Services | Director/Board Member | |
Chiral Quest (Suzhou) Co., Ltd.
Chiral Quest (Suzhou) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Chiral Quest (Suzhou) Co. Ltd. provides drug discovery services. It focuses on the development and manufacture of chiral catalysts, development of synthetic processes, and a technology applications platform. Its products include a, b, and Cyclicb-amino acids; b-hydroxy acids; chiral amines, alcohols, amino alcohols, and pyrrolidines; succinates; and achiral compounds, a-hydroxy acids, and APIs and intermediates. Chiral Quest has one manufacturing site in Jiangxi province, and three overseas offices in USA, Europe & India respectively. The company was founded by Xumu Zhang in 2000 and is headquartered in Suzhou, China. | Miscellaneous Commercial Services | Director/Board Member |
Statistics
International
China | 8 |
Cayman Islands | 2 |
United Kingdom | 2 |
Sectoral
Health Technology | 4 |
Commercial Services | 3 |
Consumer Services | 2 |
Finance | 2 |
Operational
Director/Board Member | 7 |
Corporate Officer/Principal | 2 |
Independent Dir/Board Member | 1 |
Undergraduate Degree | 1 |
Most connected contacts
Insiders | |
---|---|
Xue Bo Zeng | 10 |
- Stock Market
- Insiders
- Fan Qing Meng
- Company connections